Database	Search items
	(Macular Degeneration [MeSH] OR Macular
	Degeneration [text word] OR Macular
	Degenerations [text word] OR Age-Related
	Maculopathies [text word] OR Macular
	Dystrophy[text word] OR Macular Dystrophies
PubMed	[text word] OR Age-Related Macular
	Degeneration[text word] OR Age-Related
	Macular Degenerations[text word] OR Age-
	Related Maculopathy [text word] OR Age-Related
	Maculopathies [text word]) AND (aflibercept
	[Supplementary Concept] OR aflibercept [text
	word] OR eylea [text word])
	('macular degeneration' OR 'macular
	degenerations' OR 'macular dystrophy' OR
	'macular dystrophies' OR 'macular atrophy' OR
Embase	'macular atrophies' OR 'atrophia maculae luteae'
Embase	OR 'bilateral macular degeneration' OR
	'degeneratio maculae luteae retinae' OR
	'disciform macular degeneration' OR
	'heredomacular degeneration') AND ('aflibercept'
	OR 'eylea')


## Supplementary Table S1. Terms used for literature search


## Supplementary Table S2. Quality Assessment of cohort studies based on Newcastle Ottawa Scale


Study ID	Sample Size	Selection				Comparability		Outcome		Total Stars	
		\$1	S2	S3	S4 (a)	C1	C2	01	02	03	- Iotal Star
Au et al. 2016	88 eyes (Ranibizumab group: 23 Aflibercept group: 30 bevacizumab: 35)	*	*	+	*	*		*	*	*	7
Balaskas et al. 2016	102 patients (Ranibizumab group: 50 Aflibercept group: 52)	*	*	*	*	*		*	*	*	8
Cho et al. 2016	98 eyes (Ranibizumab group: 60 Aflibercept group: 38)	*	*	*	*	*	*	*	*	*	9
Dirani et al. 2015	115 eyes (Ranibizumab group: 68 Aflibercept group: 47)	*	*	+	*			*	*		5
Garweg et al 2017	153 eyes (Ranibizumab group: 47 Aflibercept group: 106)	*	*	*	*			*	*	*	7
Gillies et al. 2016	394 eyes (Ranibizumab group: 197 Aflibercept group: 197)	*	*	*	*	*		*	*	*	8
Hata et al. 2014	216 eyes (Ranibizumab group: 133 Aflibercept group: 83)	*	*	*	*		*	*	*	*	8
Inoue et al. 2016	200 eyes (Ranibizumab group: 99 Aflibercept group: 101)	*	*	+	*		*	*	*	*	7
Kano et al. 2015	103 eyes (Ranibizumab group: 74 Aflibercept group: 29)	*	*	*	*	*	*	*	*		8
Kim et al. 2016	51 eyes (Ranibizumab group: 30 Aflibercept group: 21)	*	*	+	*	*	*	*	*	*	8
Lee et al. 2017	1884 eyes (Ranibizumab group: 942 Aflibercept group: 942)	*		*	*		*	*	*	*	7
Notes	+. Based on the method desc assessment was found in the		exposure sho	ould be estir	nated based	on medica	ll records, bu	it no detaile	d descriptior	about sour	ce of

Study ID	Sample Size	Selection				Comparability		Outcome			Total Stars
		<b>S1</b>	S2	S3	S4 (a)	C1	C2	01	02	03	1
Lotery et al. 2017	7650 eyes (Ranibizumab group: 3350 Aflibercept group: 4300)	*	*	*	*			*	*	*	7
Miyamoto et al. 2017	148 eyes (Ranibizumab group: 77 Aflibercept group: 71)	*	*	*	*			*	*	*	7
Park et al. 2016	232 eyes (Ranibizumab group: 87 Aflibercept group: 74 bevacizumab: 71)		*	+	*	*	*	*	*		6
Rasmussen et al. 2017	1143 eyes (Ranibizumab group: 616 Aflibercept group: 527)	*	*	*	*	*		*	*	*	8
Selid et al. 2014	202 eyes (Bevacizumab group: 111 Aflibercept group: 91)	*	*	*	*	*	*	*	*	*	9
Subhi et al. 2017	106 eyes (Ranibizumab group: 57 Aflibercept group: 49)	*	*	*	*			*	*		6
Yun et al. 2016	54 eyes (Ranibizumab group: 33 Aflibercept group: 21)	*	*	*	*		*	*	*		7
Notes	<sup>+</sup> . Based on the method description, the exposure should be estimated based on medical records, but no detailed description about source of assessment was found in the context.										

## Supplementary Table S2. Quality Assessment of cohort studies based on Newcastle Ottawa Scale (continued)







Supplementary Figure S4. Funnel plot of the differences in CRT changes after aflibercept and ranibizumab treatment at 3(A), 6(B), 12(C), and 24(D) months

5

		LogMAR change (95 <sup>o</sup> therapy	% CI) after aflibercept	Number of injections				
		Compared to baseline	Compared to ranibizumab	Compared to baseline	Compared to ranibizumab			
_	< 75	-0.14 (-0.18 to -0.09)	-0.04 (-0.10 to 0.03)	4.97 (4.37 to 5.57)	-0.87 (-2.21 to 0.47)			
Age	75-85	-0.07 (-0.13 to 0.02)	0.00 (-0.10 to 0.10)	9.00 (5.78 to 12.22)	0.58 (-0.12 to 1.28)			
(years)	≥ 85	-0.08 (-0.17 to 0.02)	-0.09 (-0.22 to 0.04)	Not available	Not available			
Baseline	≤ 0.6	-0.09 (-0.14 to -0.05)	-0.03 (-0.09 to 0.03)	7.53 (5.31 to 9.75)	0.32 (-0.15 to 0.79)			
LogMAR	> 0.6	-0.12 (-0.14 to -0.11)	-0.08 (-0.11 to -0.06)	5.47 (4.16 to 6.78)	-0.69 (-2.34 to 0.96)			
	Asia	-0.14 (-0.18 to -0.09)	-0.04 (-0.10 to 0.03)	4.97 (4.37 to 5.57)	-0.87 (-2.21 to 0.47)			
Study areas	Europe	-0.11 (-0.14 to -0.08)	-0.07 (-0.13 to -0.01)	7.22 (6.74 to 7.71)	0.32 (-0.81 to 1.46)			
	US	0.03 (-0.19 to 0.25)	-0.07 (-0.35 to 0.21)	10.8 (8.80 to 12.80)	0.10 (-3.28 to 3.48)			
Treatment regimens	Fixed dosing or Treatment and extend	-0.11 (-0.15 to -0.07)	-0.05 (-0.15 to 0.04)	7.22 (6.74 to 7.71)	1.00 (0.45 to 1.56)			
	3 monthly injections + PRN	-0.13 (-0.17 to -0.09)	-0.05 (-0.11 to 0.01)	4.97 (4.37 to 5.57)	-0.93 (-2.07 to 0.22)			
Subtypes of wet AMD	Typical	-0.13 (-0.19 to -0.07)	-0.03 (-0.12 to 0.06)	4.78 (4.19 to 5.36)	-0.10 (-0.60 to 0.39)			
	PCV	-0.13 (-0.20 to -0.06)	-0.03 (-0.13 to 0.08)	5.13 (4.33 to 5.94)	-0.38 (-0.91 to 0.14)			
	With PED	0.03 (-0.19 to 0.25)	-0.07 (-0.35 to 0.21)	10.8 (8.80 to 12.80)	0.10 (-3.28 to 3.48)			
Note	LogMAR = logarithm of minimum angle of resolution; CRT = central retinal thickness; CI = confidence interval; PCV = polypoidal choroidal vasculopathy; PED = pigment epithelial detachment							

## Supplementary Table S5. Subgroup Analysis at 12-month of follow up (sensitivity analysis)